Mexico grants Quick-Med Technologies, Inc. Notice of Allowance for its NIMBUS® Technology

Gainesville, Florida - August 2, 2007 - Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT) ("Quick-Med Technologies" or the "Company") announced today a patent was allowed by the Mexican Patent Office, Instituto Mexicano de la Propiedad Industrial, to protect the Company's intellectual property involving its NIMBUS® technology.

The patent titled "Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication", has claims that cover the composition of permanently bonded antimicrobial absorbent materials and the process for producing them. Similar patents have now been allowed in the U.S., China, Australia, Russia, and Indonesia.

"We are pleased that the patents underlying our intellectual property continue to issue globally, supporting our efforts to expand into promising international markets," said David S. Lerner, President of Quick-Med Technologies. "This allowance is particularly significant because it affords protection to our IP in a venue where the opportunity to produce medical devices can be accomplished at a very low cost." added Mr. Lerner.

Additional information regarding Quick-Med Technologies' Intellectual portfolio can be found in the Company's Form 10-KSB filed with the Securities and Exchange Commission.

About NIMBUST
The Company's patented technology, NIMBUS®, employs a family of advanced antimicrobial polymers that destroy bacteria at the cellular level, thereby eliminating the risk of developing drug resistance. Unlike any other microbicide on the market today, the NIMBUS technology works by creating a permanent bond with a multitude of substrates (without leaching) and is less than 10% the cost of silver-based antimicrobials. NIMBUS is highly effective, including against methicillin-resistant Staphylococcus aureus ("MRSA") and vancomycin-resistant Enterococcus ("VRE"), two of the most significant antibiotic-resistant organisms responsible for hospital infections.

About Quick-Med Technologies, Inc.
Quick-Med Technologies is a life sciences company focused in developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company¹s two core products under development are (1) MultiStat™, a family of advanced compounds shown to be effective in broad-based skin therapy applications, and (2) NIMBUS™, a family of advanced polymers that can be used in a wide range of applications from advanced wound care to wood preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies¹ website: www.quickmedtech.com or email: info@quickmed-technologies.com

For additional further information, please contact QMT:

David S. Lerner -- President
Phone : (561) 750-4202
Email: dlerner@quickmed-technologies.com

Natasha A. Sorobey -- Corporate & Investor Relations (Canada)
Phone: (403) 203-4748
Email: nsorobey@quickmed-technologies.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.